In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae

被引：54

作者：

Patel, R ^{[1
]}

Rouse, MS ^{[1
]}

Piper, KE ^{[1
]}

Steckelberg, JM ^{[1
]}

机构：

[1] Mayo Clin & Mayo Fdn, Div Infect Dis & Internal Med, Dept Internal Med, Rochester, MN 55902 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 1999年 / 34卷 / 02期

关键词：

D O I：

10.1016/S0732-8893(99)00016-4

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We report the activity of the new oxazolidinone antimicrobial agent linezolid against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 20 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by less than or equal to 4 mu g/ml of linezolid. All isolates of methicillin-resistant S. aureus were inhibited by less than or equal to 8 mu g/ml of linezolid. All isolates of penicillin-resistant S. pneumoniae were inhibited by less than or equal to 2 mu g/ml of linezolid. Linezolid inhibits strains of multidrug resistant Grampositive cocci in vitro at concentrations less than or equal to 8 mu g/ml. (C) 1999 Elsevier Science Inc.

引用

页码：119 / 122

页数：4

共 17 条

[1]

*CDC, 1997, MMWR-MORBID MORTAL W, V46, P813

[2]

CDC, 1993, MMWR-MORBID MORTAL W, V42, P597

[3] In vitro activities of new oxazolidinone antimicrobial agents against enterococci [J].

Eliopoulos, GM ;

Wennersten, CB ;

Gold, HS ;

Moellering, RC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (07) :1745-1747

[4] In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections [J].

Ford, CW ;

Hamel, JC ;

Wilson, DM ;

Moerman, JK ;

Stapert, D ;

Yancey, RJ ;

Hutchinson, DK ;

Barbachyn, MR ;

Brickner, SJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1508-1513

[5] INVIVO DEVELOPMENT OF TEICOPLANIN RESISTANCE IN A VANB ENTEROCOCCUS-FAECIUM ISOLATE [J].

HAYDEN, MK ;

TRENHOLME, GM ;

SCHULTZ, JE ;

SAHM, DF .

JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (05) :1224-1227

[6] In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species [J].

Jorgensen, JH ;

McElmeel, ML ;

Trippy, CW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :465-467

[7] In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae [J].

Mason, EO ;

Lamberth, LB ;

Kaplan, SL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :1039-1040

[8] In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis [J].

Mulazimoglu, L ;

Drenning, SD ;

Yu, VL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2428-2430

[9]

*NAT COMM CLIN LAB, 1997, M7A4 NAT COMM CLIN L

[10]

*NAT COMM CLIN LAB, 1992, METH DET BACT ACT AN

← 1 2 →